Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 May;60(5):453–458. doi: 10.1136/ard.60.5.453

Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis

J Albers 1, L Paimela 1, P Kurki 1, K Eberhardt 1, P Emery 1, Hof M A van `t 1, F Schreuder 1, M Leirisalo-Repo 1, P L C M van Riel 1
PMCID: PMC1753652  PMID: 11302866

Abstract

OBJECTIVE—To compare four different inception cohorts of patients with early rheumatoid arthritis (RA) with respect to treatment strategies, disease activity, and outcome during a five year follow up period.
METHOD—Data from cohorts of patients with early RA, with a standardised assessment at least every six months for five years from four different centres, were included in one database. Owing to slight differences in the individual study designs, linearly interpolated values were calculated to complete the standard follow up schedule.
RESULTS—Despite similar inclusion criteria, significant differences in demographic factors and baseline disease activity were found between the different cohorts. During the follow up an aggressive treatment strategy was followed in the Dutch and Finnish cohort, an intermediate strategy in the British cohort, and a conservative strategy in the Swedish cohort. A significant improvement in disease activity was seen in all cohorts, though the most rapid and striking improvement was seen in those receiving aggressive treatment. This resulted in less radiographic destruction in the long run.
CONCLUSION—This observational study of cohorts of patients with early RA confirms that early aggressive treatment results not only in a more rapid reduction of disease activity but also in less radiographic progression in the long term.



Full Text

The Full Text of this article is available as a PDF (172.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

The course of the disease during the five year follow up period (median values and 95% confidence intervals). ESR = erythrocyte sedimentation rate; VAS = visual analogue scale; RAI = Ritchie Articular Index; DAS = disease activity score.

Figure 2  .

Figure 2  

Open in a new tab

Median radiographic (Larsen) scores (95% confidence intervals).

Figure 3  .

Figure 3  

Open in a new tab

Dutch median radiographic (Sharp) scores (95% confidence intervals).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., van Zeben D., Dijkmans B. A., Peeters A. J., Jacobs P. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–318. doi: 10.1016/S0140-6736(97)01300-7. [DOI] [PubMed] [Google Scholar]
  3. Combe B., Bertin P. Polyarthrite rhumatoïde: stratégies thérapeutiques. Presse Med. 1998 Dec 12;27(39):2070–2074. [PubMed] [Google Scholar]
  4. Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., Meusser S., Paimela L., Rau R., Zeidler H. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999 Apr;58(4):220–225. doi: 10.1136/ard.58.4.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Egsmose C., Lund B., Borg G., Pettersson H., Berg E., Brodin U., Trang L. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol. 1995 Dec;22(12):2208–2213. [PubMed] [Google Scholar]
  6. Emery P. Early rheumatoid arthritis: therapeutic strategies. Scand J Rheumatol Suppl. 1994;100:3–7. doi: 10.3109/03009749409095196. [DOI] [PubMed] [Google Scholar]
  7. Emery P., Symmons D. P. What is early rheumatoid arthritis?: definition and diagnosis. Baillieres Clin Rheumatol. 1997 Feb;11(1):13–26. doi: 10.1016/s0950-3579(97)80030-1. [DOI] [PubMed] [Google Scholar]
  8. Farr M., Bacon P. A. How and when should combination therapy be used? The role of an anchor drug. Br J Rheumatol. 1995 Nov;34 (Suppl 2):100–103. [PubMed] [Google Scholar]
  9. Ferraccioli G. F., Bambara L. M., Ferraris M., Perpignano G., Cattaneo R., Porzio F., Accardo S., Mattara L., Zoppini A., Benucci M. Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis. Clin Exp Rheumatol. 1997 May-Jun;15 (Suppl 17):S83–S89. [PubMed] [Google Scholar]
  10. Fries J. F., Williams C. A., Morfeld D., Singh G., Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996 Apr;39(4):616–622. doi: 10.1002/art.1780390412. [DOI] [PubMed] [Google Scholar]
  11. Gremillion R. B., van Vollenhoven R. F. Rheumatoid arthritis. Designing and implementing a treatment plan. Postgrad Med. 1998 Feb;103(2):103-6, 110, 116-8 passim. doi: 10.3810/pgm.1998.02.314. [DOI] [PubMed] [Google Scholar]
  12. Haagsma C. J., van Riel P. L., de Jong A. J., van de Putte L. B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997 Oct;36(10):1082–1088. doi: 10.1093/rheumatology/36.10.1082. [DOI] [PubMed] [Google Scholar]
  13. Hannonen P., Möttönen T., Hakola M., Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 1993 Nov;36(11):1501–1509. doi: 10.1002/art.1780361104. [DOI] [PubMed] [Google Scholar]
  14. Kroot E. J., van Leeuwen M. A., van Rijswijk M. H., Prevoo M. L., Van 't Hof M. A., van De Putte L. B., van Riel P. L. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis. 2000 Dec;59(12):954–958. doi: 10.1136/ard.59.12.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Larsen A., Dale K., Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977 Jul;18(4):481–491. doi: 10.1177/028418517701800415. [DOI] [PubMed] [Google Scholar]
  16. Lindqvist E., Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis. 1999 Jan;58(1):11–14. doi: 10.1136/ard.58.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Matsuda Y., Yamanaka H., Higami K., Kashiwazaki S. Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis. J Rheumatol. 1998 Mar;25(3):427–432. [PubMed] [Google Scholar]
  18. Menninger H., Herborn G., Sander O., Blechschmidt J., Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol. 1998 Oct;37(10):1060–1068. doi: 10.1093/rheumatology/37.10.1060. [DOI] [PubMed] [Google Scholar]
  19. Möttönen T., Hannonen P., Leirisalo-Repo M., Nissilä M., Kautiainen H., Korpela M., Laasonen L., Julkunen H., Luukkainen R., Vuori K. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999 May 8;353(9164):1568–1573. doi: 10.1016/s0140-6736(98)08513-4. [DOI] [PubMed] [Google Scholar]
  20. Möttönen T., Paimela L., Ahonen J., Helve T., Hannonen P., Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum. 1996 Jun;39(6):996–1005. doi: 10.1002/art.1780390617. [DOI] [PubMed] [Google Scholar]
  21. Möttönen T., Paimela L., Leirisalo-Repo M., Kautiainen H., Ilonen J., Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis. 1998 Sep;57(9):533–539. doi: 10.1136/ard.57.9.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rau R., Herborn G., Menninger H., Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol. 1998 Nov;37(11):1220–1226. doi: 10.1093/rheumatology/37.11.1220. [DOI] [PubMed] [Google Scholar]
  23. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  24. Stenger A. A., Van Leeuwen M. A., Houtman P. M., Bruyn G. A., Speerstra F., Barendsen B. C., Velthuysen E., van Rijswijk M. H. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol. 1998 Nov;37(11):1157–1163. doi: 10.1093/rheumatology/37.11.1157. [DOI] [PubMed] [Google Scholar]
  25. Stenger A. A., Van Leeuwen M. A., Houtman P. M., Bruyn G. A., Speerstra F., Barendsen B. C., Velthuysen E., van Rijswijk M. H. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol. 1998 Nov;37(11):1157–1163. doi: 10.1093/rheumatology/37.11.1157. [DOI] [PubMed] [Google Scholar]
  26. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995 Nov;9(4):619–632. doi: 10.1016/s0950-3579(05)80305-x. [DOI] [PubMed] [Google Scholar]
  27. Wollheim F. A., Eberhardt K. B., Johnson U., Saxne T. HLA DRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis. Br J Rheumatol. 1997 Aug;36(8):847–849. doi: 10.1093/rheumatology/36.8.847. [DOI] [PubMed] [Google Scholar]
  28. Young A., van der Heijde D. M. Can we predict aggressive disease? Baillieres Clin Rheumatol. 1997 Feb;11(1):27–48. doi: 10.1016/s0950-3579(97)80031-3. [DOI] [PubMed] [Google Scholar]
  29. van Gestel A. M., Haagsma C. J., Furst D. E., van Riel P. L. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Baillieres Clin Rheumatol. 1997 Feb;11(1):65–82. doi: 10.1016/s0950-3579(97)80033-7. [DOI] [PubMed] [Google Scholar]
  30. van Leeuwen M. A., van der Heijde D. M., van Rijswijk M. H., Houtman P. M., van Riel P. L., van de Putte L. B., Limburg P. C. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol. 1994 Mar;21(3):425–429. [PubMed] [Google Scholar]
  31. van Zeben D., Breedveld F. C. Prognostic factors in rheumatoid arthritis. J Rheumatol Suppl. 1996 Mar;44:31–33. [PubMed] [Google Scholar]
  32. van de Putte L. B., van Gestel A. M., van Riel P. L. Early treatment of rheumatoid arthritis: rationale, evidence, and implications. Ann Rheum Dis. 1998 Sep;57(9):511–512. doi: 10.1136/ard.57.9.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. van der Heide A., Jacobs J. W., Bijlsma J. W., Heurkens A. H., van Booma-Frankfort C., van der Veen M. J., Haanen H. C., Hofman D. M., van Albada-Kuipers G. A., ter Borg E. J. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996 Apr 15;124(8):699–707. doi: 10.7326/0003-4819-124-8-199604150-00001. [DOI] [PubMed] [Google Scholar]
  34. van der Heijde D. M., van 't Hof M. A., van Riel P. L., Theunisse L. A., Lubberts E. W., van Leeuwen M. A., van Rijswijk M. H., van de Putte L. B. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990 Nov;49(11):916–920. doi: 10.1136/ard.49.11.916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., Gribnau F. W., vad de Putte L. B. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989 May 13;1(8646):1036–1038. doi: 10.1016/s0140-6736(89)92442-2. [DOI] [PubMed] [Google Scholar]
  36. van der Heijde D. M., van Riel P. L., van Leeuwen M. A., van 't Hof M. A., van Rijswijk M. H., van de Putte L. B. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol. 1992 Aug;31(8):519–525. doi: 10.1093/rheumatology/31.8.519. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES